IGF-1 DES Peptide: Truncated IGF-1, Mechanism and Research Limits
IGF-1 DES peptide guide on the DES(1-3) truncation, reduced IGFBP binding, increased local potency, a very short half-life, animal evidence and research limits.
IGF-1 DES is one of the most misunderstood compounds in the growth-factor space. It is a real, naturally occurring molecule with a well-documented biochemistry, yet almost everything written about human "dosing" sits far ahead of the actual evidence. The compound, properly written as des(1-3)IGF-1 or Des-IGF-1, is a truncated version of insulin-like growth factor 1 that lacks the first three amino acids at the N-terminus.
That small structural change has an outsized effect on how the peptide behaves in a test tube. It is the entire reason IGF-1 DES exists as a research tool. But the same change does not turn it into a validated human therapeutic, and the peer-reviewed record is explicit that the work has been done in cells and animals, not in approved human treatment.
This guide is educational and not medical advice. IGF-1 DES is a research-only compound with no human therapeutic approval and no established human dose. Nothing here should be read as a protocol or as encouragement to use it.
IGF-1 DES At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A truncated form of IGF-1, des(1-3)IGF-1, missing the N-terminal tripeptide glycine-proline-glutamate. |
| Where was it found? | First isolated and sequenced from human fetal and adult brain tissue in 1986. |
| Main receptor | The type 1 IGF receptor (IGF-1R), with affinity similar to native IGF-1. |
| Defining feature | Roughly 1 percent of native IGF-1's affinity for IGF-binding proteins, so more peptide stays free. |
| Potency note | About tenfold more mitogenic than IGF-1 in cultures containing binding proteins; similar when binding proteins are absent. |
| Half-life | Very short; clears from blood faster than IGF-1 in animal studies. |
| Evidence type | Cell culture and animal experiments only. No human therapeutic approval. |
What IGF-1 DES Actually Is
Native IGF-1 is a 70-amino-acid peptide that drives growth and anabolic signaling throughout the body. IGF-1 DES is the same molecule with one edit: the first three residues, glycine-proline-glutamate (Gly-Pro-Glu), have been removed from the N-terminus, leaving a 67-residue peptide.
This is not a synthetic invention. Sara, Carlsson-Skwirut and colleagues identified the truncated variant in human fetal brain in 1986, and a companion report characterized variant IGF-1 and IGF-2 from adult human brain the same year. In other words, des(1-3)IGF-1 is an endogenous form of IGF-1 that the body itself produces in certain tissues, and it has also been isolated from sources such as bovine colostrum.
The three internal disulfide bonds, the receptor-binding surface and the overall fold of the molecule are preserved. What changes is the peptide's relationship with the IGF-binding proteins, and that single shift explains its entire research profile.
For background on how peptides are defined and named, see what peptides are, and for why the half-life detail below matters so much, see the peptide half-life guide.
Mechanism: Less Binding-Protein Capture, More Free Peptide
In the bloodstream and in tissues, the great majority of IGF-1 is not free. It is held by a family of IGF-binding proteins (IGFBPs), especially IGFBP-3, which control how much IGF-1 can reach the type 1 IGF receptor at any moment. Binding proteins act as a reservoir and a brake.
The N-terminal tripeptide that IGF-1 DES is missing turns out to be important for that capture. Szabo and colleagues showed that the binding protein released by cultured cells requires the N-terminal region of IGF-1 to bind it well. Strip those residues away and the interaction collapses. Reviews of des(1-3)IGF-1 describe an average affinity for IGFBPs of only about 1 percent of native IGF-1's, with biosensor and competition data putting the loss for IGFBP-3 somewhere in the 25-fold to 100-fold range depending on method.
Crucially, the receptor-facing part of the molecule is untouched. IGF-1 DES binds and activates the type 1 IGF receptor (IGF-1R) with affinity close to that of intact IGF-1. So the peptide is not intrinsically a stronger receptor activator. Instead, by dodging binding-protein sequestration, more of it stays free to reach the receptor.
Ross, Francis, Szabo, Wallace and Ballard demonstrated this directly in 1989 in the Biochemical Journal. Binding proteins from cultured kidney cells strongly inhibited the biological activity of IGF-1 and IGF-2, but had essentially no inhibitory effect on des(1-3)IGF-1. The authors concluded that biological potency correlated inversely with how tightly each peptide was bound by the proteins in the medium. That is the mechanism in a single sentence: potency in binding-protein-rich conditions tracks how well a peptide escapes the binding proteins.
Evidence, And Its Limits
The honest framing is that IGF-1 DES has a real but narrow evidence base, built almost entirely from cell culture and rodent studies in the late 1980s and early 1990s.
| Setting | What the research supports | Important limit |
|---|---|---|
| Cell culture with binding proteins | Roughly tenfold greater mitogenic potency than IGF-1. | The advantage shrinks toward parity once binding proteins are removed. |
| Gut resection in rats | IGF-1 and des(1-3)IGF-1 both improved weight gain and nitrogen balance after surgery. | Effects were broadly comparable to high-dose IGF-1, not dramatically superior. |
| Diabetic and nitrogen-restricted rats | Improved nitrogen retention and muscle protein synthesis; favored lean tissue. | These are short infusion studies in stressed animals, not human trials. |
| Diabetic rat retina | Des(1-3)IGF-1 normalized IGF-1 receptor and phospho-Akt immunoreactivity in predegenerative retina. | A tissue-signaling study, not evidence of a human treatment. |
The cell-potency claim comes from work like the 1989 Ross study and later reviews: in cultures that contain IGFBPs, des(1-3)IGF-1 is about ten times more mitogenic than IGF-1. The anabolic animal work is led by the Adelaide group. Lemmey and colleagues (1991) showed both IGF-1 and des(1-3)IGF-1 enhanced growth recovery in rats after removal of most of the small intestine. Tomas and colleagues reported increased weight gain, nitrogen retention and muscle protein synthesis in diabetic rats, and improved nitrogen balance in nitrogen-restricted rats, with the truncated analogue active at low doses.
What the literature does not contain is the part people most want: validated human efficacy, safety and dosing. The compound has been a probe for IGF biology, used precisely because its short half-life and binding-protein evasion make it a clean experimental tool. Pan and Kastin (2000) used it for exactly that reason, noting its short half-life in blood and little protein binding when studying transport at the blood-brain barrier.
Safety Considerations
There is no human safety dataset for IGF-1 DES of the kind that exists for an approved drug. The concerns below are inferred from IGF biology and from the general risks of strong growth-factor signaling, not from controlled human trials. They are reasons for caution, not a monitoring plan.
| Safety issue | Why it matters |
|---|---|
| Hypoglycemia | IGF-1 signaling overlaps with insulin signaling and can lower blood glucose; potent local activation raises this concern. |
| Unregulated growth signaling | IGF-1R activation is mitogenic; sustained or excessive signaling is a theoretical concern for abnormal tissue growth. |
| No purity or dosing standards | Research-market material has no human-grade manufacturing, labeling or dose validation. |
| Very short half-life | Rapid clearance makes exposure hard to predict and was a research feature, not a treatment advantage. |
| No human trial data | Effects, interactions and long-term consequences in people are simply unstudied. |
For a broader discussion of the risks shared across this family of compounds, see growth-hormone peptide side effects.
How IGF-1 DES Compares To IGF-1 LR3 And The MGF Family
IGF-1 DES is often discussed alongside two other IGF-1 relatives, and the contrast is instructive.
IGF-1 LR3 is an engineered analogue that adds an N-terminal extension and a single residue substitution. Like DES, it has reduced IGFBP affinity, but its design goal is the opposite end of the kinetic spectrum: a much longer half-life, reported in the range of many hours rather than minutes. So DES and LR3 are two solutions to the same binding-protein problem, one extremely short-acting and one long-acting.
The MGF family is different again. MGF, or mechano growth factor, is a splice variant of the IGF-1 gene with its own C-terminal peptide and a proposed local, repair-oriented signaling role rather than systemic IGF-1R agonism in the same sense. Its pegylated form is covered in the PEG-MGF guide. The practical point is that "IGF-1 variant" is not one category: DES, LR3 and MGF differ in structure, kinetics and the questions researchers use them to ask.
These IGF-1 variants also sit apart from the growth-hormone secretagogues that people sometimes lump them with. Compounds like ipamorelin and CJC-1295 work upstream by influencing growth hormone release, not by directly activating the IGF-1 receptor. Mixing these mechanisms together under one wellness banner ignores how differently they behave.
Bottom Line
IGF-1 DES is a genuine, naturally occurring truncated form of IGF-1, and its biology is well characterized. Removing the N-terminal tripeptide cripples its binding to IGF-binding proteins while leaving its grip on the type 1 IGF receptor intact. In conditions where binding proteins are present, that makes it markedly more potent than native IGF-1, and it travels with a very short half-life.
But the same record that makes the mechanism clear also marks its limits. The evidence is cell-culture and animal work, much of it decades old, designed to probe IGF biology rather than to support a human treatment. There is no human therapeutic approval, no validated dose and no human safety dataset, and the plausible concerns, from hypoglycemia to unregulated growth signaling, all argue for treating it as exactly what it is: a research compound.
References
Sara VR, Carlsson-Skwirut C, Andersson C, et al. Characterization of somatomedins from human fetal brain: identification of a variant form of insulin-like growth factor I. Proc Natl Acad Sci USA. 1986.
Carlsson-Skwirut C, Jörnvall H, Holmgren A, et al. Isolation and characterization of variant IGF-1 as well as IGF-2 from adult human brain. FEBS Lett. 1986.
Ross M, Francis GL, Szabo L, Wallace JC, Ballard FJ. Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. Biochem J. 1989.
Lemmey AB, Martin AA, Read LC, Tomas FM, Owens PC, Ballard FJ. IGF-I and the truncated analogue des-(1-3)IGF-I enhance growth in rats after gut resection. Am J Physiol. 1991.
Tomas FM, Knowles SE, Owens PC, et al. Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I. Biochem J. 1991.
Tomas FM, Knowles SE, Owens PC, et al. Effects of full-length and truncated insulin-like growth factor-I on nitrogen balance and muscle protein metabolism in nitrogen-restricted rats. J Endocrinol. 1991.
Kummer A, Pulford BE, Ishii DN, Seigel GM. Des(1-3)IGF-1 treatment normalizes type 1 IGF receptor and phospho-Akt (Thr 308) immunoreactivity in predegenerative retina of diabetic rats. Int J Exp Diabesity Res. 2003.
Pan W, Kastin AJ. Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. Neuroendocrinology. 2000.